BioNTech SE - ADR vs Centrus Energy Corp — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Centrus Energy Corp trades at $160.68 (market cap $3.14B). The key difference: BioNTech SE - ADR is far larger — about 7.3× Centrus Energy Corp's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| BNTX | LEU | |
|---|---|---|
Market Cap | $22.86B | $3.14B |
Sector | Health | Energy |
52-Week High | $119.34 | $436.00 |
52-Week Low | $83.89 | $146.61 |
Enterprise Value | $6.53B | $2.45B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Centrus Energy (LEU) trades at $156.05, down 8.77% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 57.96 but strong net income margin of 13.4%. Recent positive developments include a $1 billion DOE contract expansion and inclusion in the S&P SmallCap 600 index, though earnings have been inconsistent with two misses and one beat in recent quarters.
The outlook remains cautiously optimistic given strong government contracts and nuclear industry tailwinds, but elevated valuation and recent earnings volatility present risks. Analyst consensus price target of $223.14 suggests 43% upside potential, though technical indicators signal near-term bearish pressure with support at $151.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →